glp-1 and gip receptor agonist Frontiers Frontiers | The evolution of

The Medication Thats Rewriting Weight-Loss Rules Published Date: September 2, 2025 Introduction - From blood sugar control to body weight transformation Until very recently, medical therapy for obesity delivered only modest wins

Additionally, restarting home medications before discharge improves transitions of care

D., Mller, T

Releasing insulin

Clinical Efficacy: Evidence from Major Trials Weight Loss Outcomes in Non-Diabetic Patients The clinical efficacy of GLP-1 agonists for weight loss in non-diabetic patients has been demonstrated across multiple large-scale randomized controlled trials

139 Although generally well tolerated, meta-analysis of 14 clinical trials suggests that long-acting GLP-1RAs (eg, semaglutide, tirzepatide) are associated with lower rates of gastrointestinal side-effects, particularly nausea and vomiting, compared to short-acting agents (Table 2)